J. Grimes

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

M A Fischl, M D Hughes, S. Hammer, 1997, The New England journal of medicine.

The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group.

J. Phair, M. Hirsch, S. Lagakos, 1994, JAMA.

Differences Between Women and Men in Adverse Events and CD4+ Responses to Nucleoside Analogue Therapy for HIV Infection

S. Hammer, D. Katzenstein, C. Spino, 2000, Journal of acquired immune deficiency syndromes.

Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus.

S. Lagakos, D. Richman, J. Grimes, 1990, Journal of acquired immune deficiency syndromes.

Predictors of Virologic and Clinical Outcomes in HIV-1Infected Patients Receiving Concurrent Treatment with Indinavir, Zidovudine, and Lamivudine: AIDS Clinical Trials Group Protocol 320

S. Hammer, M. Hughes, S. Spector, 2001, Annals of Internal Medicine.

Effect of HIV‐specific immune‐based therapy in subjects infected with HIV‐1 subtype E in Thailand

W. Sirawaraporn, R. Moss, F. Jensen, 1998, AIDS.

A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.

J. Phair, M. Hirsch, S. Lagakos, 1995, The New England journal of medicine.

Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team.

S. Hammer, D. Katzenstein, C. Spino, 2000 .